SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Zhu, B.-q.
Right arrow Articles by Karliner, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, B.-q.
Right arrow Articles by Karliner, J. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Comparison of Pyrroloquinoline Quinone and/or Metoprolol on Myocardial Infarct Size and Mitochondrial Damage in a Rat Model of Ischemia/Reperfusion Injury

Bo-qing Zhu, MD, FACC

Cardiology Section, VA Medical Center, Department of Medicine, University of California, San Francisco

Ursula Simonis, PhD

Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California

Gary Cecchini, PhD

Molecular Biology Division, VA Medical Center, Department of Biochemistry and Biophysics, University of California, San Francisco

Hui-zhong Zhou, MD

Cardiology Section, VA Medical Center, Department of Medicine, University of California, San Francisco

Luyi Li, MD

Cardiology Section, VA Medical Center, University of California, San Francisco

John R. Teerlink, MD, FACC

Cardiology Section, VA Medical Center, Department of Medicine, University of California, San Francisco

Joel S. Karliner, MD, FACC

Cardiology Section, VA Medical Center, Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, joel.karliner{at}med.va.gov

The cardioprotective effectiveness of low-dose pyrroloquinoline quinone (PQQ, 3 mg/kg) was compared with metoprolol, a ß1-selective adrenoceptor antagonist. Rats underwent 30 minutes of left anterior descending coronary artery occlusion and 2 hours of reperfusion. Metoprolol and/or PQQ were given at the onset of reperfusion to mimic clinical treatment. Metoprolol and/or PQQ reduced infarct size and protected against ischemia-induced left ventricular dysfunction after 2 hours of reper-fusion. Combined therapy augmented left ventricular developed pressure at the end of reperfusion. Metoprolol or PQQ alone enhanced mitochondrial respiratory ratios in ischemic and nonischemic myocardium. Although the PQQ/metoprolol combination therapy increased respiratory ratio values, the effects were small when compared with PQQ alone. Only PQQ decreased lipid peroxidation. Metoprolol and/or PQQ given at the onset of reperfusion reduce infarct size and improve cardiac function. Combination therapy further reduces infarct size. PQQ is superior to metoprolol in protecting mitochondria from ischemia/reperfusion oxidative damage

Key Words: pyrroloquinoline quinone • metoprolol • ischemia/reperfusion

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 2, 119-128 (2006)
DOI: 10.1177/1074248406288757


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement